Published on : Jun 01, 2018
Albany, New York, June 1, 2018: The scleroderma disease is gaining attention from various governments and research organizations, mainly due to unmet needs of the segment and high disability rate associated with the disease. According to the findings of the latest study, the market for scleroderma therapeutics set to grow rapidly in the near future due to the increasing focus globally on the treatment of orphan diseases. Market Research Hub (MRH) has freshly publicized this study to its massive database, which is titled as “Scleroderma Diagnostics and Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2024”. The study offers vital insights on the impact of recent trends and developments in the growth of the market.
In order to deliver accurate results, this comprehensive study on scleroderma diagnostics consists of market size, Y-o-Y growth and CAGR during the estimated period of 2017-2024. The report majorly covers different sections on market definition, market dynamics including the key drivers, restraints and trends that are governing the market. To pour more light on this, geographical analysis has been presented. The regional analysis section is a crucial segment of the report, which enlightens the reader about the market size and forecast for each region. Regions underlined in the study are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Key Highlights from the Study
- The term scleroderma is defined as the hardening of the skin; however, it is much more than the skin disorder. It is basically a rare connective tissue disease that can affect skin, joints, tendons and internal organs. Presently, there is no approved drug for treatment of this orphan disease. Although drugs to manage symptomatic relief are available in the scleroderma therapeutics market. Due to this, the market is highly dynamic. According to the research key findings, the global scleroderma diagnostics and therapeutics market is projected to expand at a CAGR of 10.3% from 2017 to 2024 and to reach US$3,663.8 mn by 2024. In 2017, the market was valued at US$1,689.7 mn.
- Analyst has further analyzed that rise in clinical trials for systemic sclerosis, high acceptance of new therapies by patients, and new drug approvals for conditions such as pulmonary arterial hypertension, a significant symptom for certain systemic scleroderma patients are some key driving factors encouraging market growth of scleroderma therapeutics market.
- Further, the report offers comprehensive information to the readers about the parameters that shape the market. The market has been segmented on the basis of drug class, indication, test type and geography. From a geographical standpoint, North America and Europe held a substantial share of the global scleroderma therapeutics market in the recent past. It is further expected to retain their dominance throughout the forecast period.
At last, the concluding section of the report deals with the company market share analysis of key players operating in this industry. Bayer AG, Actelion Pfizer, Inc., Cytori Therapeutics, Inc., Pharmaceuticals, Inc., Corbus Pharmaceutical Holdings Inc, Cumberland Pharmaceuticals, Inc., Boehringer Ingelheim, Gilead Sciences, Inc., and Sanofi are some of the key players operating in the global scleroderma diagnostics and therapeutics market.
Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=210272
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org